DuPont joins hands with MRM Health

To tackle a range of metabolic diseases

DuPont Nutrition & Biosciences (DuPont) has announced a collaboration with the MRM Health NV (MRM Health), a biopharmaceutical company, focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health also confirmed the successful completion of its first external investment round with the participation of Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB.

DuPont and MRM Health will join forces to tackle a range of metabolic diseases, in which the proprietary MRM Health technology platform and some selected DuPont strains will be combined to develop novel therapeutics based on live bacterial strain combinations.

The proceeds of the investment round provide MRM Health with the financing resources to advance its lead program in inflammatory bowel disease (IBD) to clinical studies in different patient populations and to further progress its ongoing discovery programs to deliver potential breakthrough treatments in Spondyloarthritis and other indications.

Through the strategic partnership with VIB, MRM Health will leverage the extensive complementary microbiome and bioinformatics capabilities of the lab of Professor Jeroen Raes, VIB – KU Leuven and the multidisciplinary know-how and patient insights in arthritis and inflammatory diseases of Professor Dirk Elewaut, VIB – UGent and his team.